Free from Publisher

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

E Kerwin, J Hébert, N Gallagher… - European …, 2012 - Eur Respiratory Soc
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist
(LAMA) in development for chronic obstructive pulmonary disease (COPD). The …
被引用次数：321 相关文章
[PDF] researchgate.net

[PDF][PDF] Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

E Kerwin, J Hébert, N Gallagher, C Martin… - EUROPEAN …, 2012 - researchgate.net
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist
(LAMA) in development for chronic obstructive pulmonary disease (COPD). The …
[PDF] psu.edu

[PDF][PDF] Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study

E Kerwin, J Hébert, N Gallagher, C Martin, T Overend… - 2012 - Citeseer
ABSTRACT NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic
antagonist (LAMA) in development for COPD. The GLycopyrronium bromide in COPD …

[引用][C] Efficacy and safety of NVA237versusplacebo and tiotropium in patients with COPD: the GLOW2 study

E Kerwin, J Hébert, N Gallagher, C Martin… - European Respiratory …, 2012 - cir.nii.ac.jp
Efficacy and safety of NVA237<i>versus</i>placebo and tiotropium in patients with COPD:
the GLOW2 study | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …

[引用][C] Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

E KERWIN, J HEBERT, N GALLAGHER… - The European …, 2012 - pascal-francis.inist.fr
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the
GLOW2 study CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study

E Kerwin, J Hébert, N Gallagher… - European …, 2012 - Eur Respiratory Soc
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist
(LAMA) in development for COPD. The GLycopyrronium bromide in COPD airWays clinical …

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

E Kerwin, J Hébert, N Gallagher, C Martin, T Overend… - 2012 - pubmed.ncbi.nlm.nih.gov
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist
(LAMA) in development for chronic obstructive pulmonary disease (COPD). The …

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.

E Kerwin, J Hébert, N Gallagher, C Martin… - The European …, 2012 - europepmc.org
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist
(LAMA) in development for chronic obstructive pulmonary disease (COPD). The …
[HTML] nih.gov

[HTML][HTML] Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

E Kerwin, J Hébert, N Gallagher, C Martin… - The European …, 2012 - ncbi.nlm.nih.gov
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist
(LAMA) in development for chronic obstructive pulmonary disease (COPD). The …
[PDF] cyberleninka.org

[PDF][PDF] Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

E Kerwin, J Hébert, N Gallagher, C Martin… - EUROPEAN …, 2012 - cyberleninka.org
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist
(LAMA) in development for chronic obstructive pulmonary disease (COPD). The …